/C O R R E C T I O N -- Decoy Therapeutics, Inc/
Decoy Therapeutics announced a refined corporate strategy to develop a pan-filovirus antiviral via the FDA Animal Rule pathway, which enables approval based on animal efficacy studies plus human safety data. Its first-generation de novo candidate showed low-micromolar potency against Ebola Zaire (IC50 1.56 uM) and Marburg virus (IC50 1.04 uM), a 7-fold improvement over remdesivir against Ebola Zaire.
Key figures
- Drug Name
- pan-filovirus D-MAV (D-MAVs)
- Phase Of Trial
- Preclinical
- Ic50 marburg u M
- 1.04
- Ic50 ebola zaire u M
- 1.56
- Potency vs remdesivir
- 7-fold improvement
- Prv market value range
- $100 million - $180 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.